Quantcast

Latest Raloxifene Stories

2009-09-15 12:38:00

ROCKVILLE, Md., Sept. 15 /PRNewswire-USNewswire/ -- Three drugs, including tamoxifen, reduce a woman's chance of getting breast cancer, but each drug carries distinct potential harms of its own, according to a new report from HHS' Agency for Healthcare Research and Quality. Drugs to reduce the risk of breast cancer can be prescribed to women with a family history of breast cancer or other risk factors, but prescribing practices vary widely. The comparative effectiveness review found that...

2009-09-14 22:32:10

Drugs used to lower the risk of breast cancer in women have the side effect of increasing the likelihood of blood clots, researchers in Oregon say. The study, published in the current issue of Annals of Internal Medicine, examined the effects of tamoxifen, raloxifene and tibolone reduce the risk of invasive breast cancer by 30 percent to 68 percent. But it also found tamoxifen and raloxifene increase the chance of blood clots by 60 percent to 90 percent, and that tiboline, which is not on the...

2009-09-13 13:47:00

DENVER, Sept. 13 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the presentation of data highlighting the links between medication satisfaction, adherence to therapy and fracture risk reduction among women with postmenopausal osteoporosis. The data were presented at the 31st annual meeting of the American Society for Bone Mineral Research (ASBMR). "These data enhance our understanding of why many women discontinue treatment with current osteoporosis therapies,...

2009-08-19 16:12:44

The Indiana pharmaceutical firm Eli Lilly has announced a potential treatment for osteoporosis had disappointing results in a five-year clinical trial. Lilly officials said Tuesday it will not apply to federal regulators for approval of arzoxifene, the Indianapolis Star reported. The announcement is a setback for Lilly. Like other pharmaceutical companies, Lilly has been struggling to find replacements for drugs losing patent protection. Evista, the company's current osteoporosis drug, goes...

2009-08-18 15:15:00

INDIANAPOLIS, Aug. 18 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women. However, the study failed to demonstrate a statistically significant difference in key secondary efficacy endpoints, such as non-vertebral fractures, clinical vertebral...

2009-04-22 18:30:00

Lilly Continues to Defend Intellectual Property Rights for Evista INDIANAPOLIS, April 22 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced that the U.S. District Court for the Southern District of Indiana today issued a preliminary injunction to prevent the launch of a generic version of Lilly's medicine Evista(R) (raloxifene HCl tablets) by Teva Pharmaceuticals until the Court renders its final ruling. Teva had indicated it was prepared to launch the generic version...

2009-04-20 09:00:00

WASHINGTON, April 20 /PRNewswire-USNewswire/ -- Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center announce the recruitment of one of the world's most respected cancer researchers, V. Craig Jordan, OBE, PhD, DSc,. Jordan joins Lombardi in July as scientific director for the cancer center and vice chairman of the department of oncology. Jordan's scientific leadership is recognized the world over. He brings an unparalleled focus to the excellent breast...

2009-04-03 15:39:00

INDIANAPOLIS, April 3 /PRNewswire-FirstCall/ --The Court of Appeals for the Federal Circuit in Washington, D.C. today overturned a lower court decision and ruled in favor of Eli Lilly and Company (NYSE: LLY) in the case of Ariad Pharmaceuticals et al. v. Eli Lilly and Company. An earlier jury decision in the U.S. District Court of Massachusetts, and a subsequent bench trial ruling, had deemed that a patent owned by Harvard University, the Massachusetts Institute of Technology and the...

2009-03-09 17:40:00

Lilly Vows to Defend Intellectual Property Rights INDIANAPOLIS, March 9 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today issued the following statement after being granted a temporary restraining order to halt the launch of a generic version of Evista(R) (raloxifene HCl tablets) by Teva Pharmaceuticals. Teva had indicated it was prepared to launch the generic version prior to the resolution of outstanding patent litigation currently being heard by the U.S. District Court for...

c0ee8b54288c2d244d323a80430aa1f41
2009-02-17 15:22:59

A large study of tibolone, a synthetic steroid used to treat menopausal symptoms and to prevent osteoporosis, was stopped six months early after researchers found that the drug substantially increased the risk of a relapse in breast cancer patients. The study, which was released Tuesday, concluded that tibolone should not be prescribed to women who had or are suspected of having breast cancer. Women with breast cancer undergoing chemotherapy sometimes experience debilitating symptoms of...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related